The Lawsuit and the Trial Data Shareholders are suing Novo Nordisk over how the company talked up its next-generation obesity drug CagriSema
Gillingham M, Van Calcar S, Ney D, Wolff J, Harding C: Dietary management of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD)
It does not establish approval, safety, or efficacy
If you are struggling with the debilitating effects of chronic inflammation, mitochondrial dysfunction, and toxic burden, supporting your body's master antioxidant pathway may be a valuable addition to your recovery toolkit
Some bodybuilders and performance athletes may gradually increase to higher dosages during short cycles, but long-term use without medical oversight is discouraged due to potential systemic effects